NCT04999995Completed
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure
To Explore the Potential of UCH-L1 as a Novel Therapeutic and Diagnostic Target in Heart Failure
Source: ClinicalTrials.gov · Last updated 12 Aug 2025
Brief summary (registry, in English)
Autophagy is considered an important component of Heart failure progression. Deubiquitination enzymes play an important role in autophagy. An important regulatory process within the autophagy pathway is ubiquitination. Ubiquitination targets proteins for degradation. On the contrary, de-ubiquitinating proteins (such as UCHL1) reverses this process. Studies have demonstrated deubiquitination to be linked to certain pathological processes, such as heart failure. UCHL1 will be examined as a potential marker of disease progression in acute decompensated heart failure.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 17 (actual)
- First submitted
- 3 Aug 2021
- Start date
- 1 Jun 2021
- Primary completion date
- 17 Mar 2025
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Heart failure
- NCT number
- NCT04999995
What you commit to
- Study type: Observational
- Participants enrolled: 17
- From 1 Jun 2021 to the primary completion date, 17 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of acute stroke (ischemic or hemorrhagic)
- Presence of intracranial hemorrhage
- History of acute stroke (ischemic or hemorrhagic) or intracranial hemorrhage within the preceding 6 months
- Active malignancy (undergoing chemotherapy, radiation therapy, or planned surgical intervention)
Lab values
- Presence of decompensated liver disease (elevated ALT/AST; ascites; Acute variceal bleeding; or hepatic encephalopathy)
- Presence of severe hyponatremia (Serum sodium \< 130 meq/L)
Other
- Mortality during inpatient observation
- Presence of sepsis
- SARS-CoV-2 positive during the current admission
Who the study is looking for
- Admission for decompensated HF (traditional diagnostic criteria will be utilized for diagnosing ADHF - presence of dyspnea as presenting complaint; evidence of volume overload - peripheral or pulmonary edema, elevated jugular venous pressure \> 10 cmH2O, presence of hepatojugular reflux, or ascites; elevated B-type Natriuretic Peptide (\>100ng/ml); evidence of pulmonary vascular congestion on chest x-ray1, or Admission for dyspnea that is NOT related to ADHF (absence of all HF symptoms and signs mentioned in ADHF inclusion criteria- except for dyspnea as presenting complaint)
- Able to give informed consent
- Age \>= 18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wm. Jennings Bryan Dorn VA Medical Center, Columbia, SC Coordinator of this site? Confirm its status | Columbia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.